Adam Friedant

Adam Friedant

Auto-generated profile, based on publicly available information

Adam Friedant

Tulane University New Orleans LA United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
EREmily M. Rencsok
Emily M. Rencsok
LBLatifa A. Bazzi
Latifa A. Bazzi
RMRana R. McKay
Rana R. McKay
FHFranklin W. Huang
Franklin W. Huang
AFAdam Friedant
Adam Friedant
LMLorelei A. Mucci
Lorelei A. Mucci
Although there are considerable racial and ethnic disparities in prostate cancer incidence and mortality in the U.S. and globally, clinical trials often do not reflect disease incidence across racial and ethnic subgroups. This study aims to comprehensively review the reporting of race and ethnicity data and the representation of race and ethnicity across prostate cancer treatment-, prevention-, and screening-based clinical trials. Seventy-two global phase III and IV prevention, screening, and treatment prostate cancer clinical trials with enrollment start dates between 1987 and 2016 were analyzed in this study, representing a total of 893,378 individual trial participants. Availability and representation of race and ethnicity data by trial funding type, temporal changes in the racial/ethnic diversity of participants, and geographic representation of countries were assessed. Of the 72 trials analyzed, 59 (81.9%) had available race data, and 11 (15.3%) of these trials additionally reported ethnicity. Of the trials reporting data, participants were overwhelmingly white men (with the highest proportion in U.S. non-publicly funded trials), comprising over 96% of the study population. The proportion of white participants in prostate cancer clinical trials has remained at over 80% since 1990. Geographically, Africa and the Caribbean were particularly underrepresented with only 3% of countries included. Trial participants continue to be majority white despite the known racial disparities in prostate cancer clinical outcomes. Current and future trials must use novel recruitment strategies to ensure enrollment of underrepresented men; targeting the inclusion of African and Caribbean medical centers is crucial to achieve equity in representation.

1 March 2015 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
AFAdam J. Friedant
Adam J. Friedant
BGBrittany M. Gouse
Brittany M. Gouse
ABAmelia K. Boehme
Amelia K. Boehme
JSJames E. Siegler
James E. Siegler
KAKaren C. Albright
Karen C. Albright
SMSheryl Martin-Schild
Sheryl Martin-Schild

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
RMRana R. McKay
Rana R. McKay
TGTheresa Gold
Theresa Gold
JZJelani C. Zarif
Jelani C. Zarif
ICIlkania M. Chowdhury-Paulino
Ilkania M. Chowdhury-Paulino
AFAdam Friedant
Adam Friedant
LMLorelei A. Mucci
Lorelei A. Mucci
Prostate cancer disproportionately affects racial and ethnic minority populations. Reasons for disparate outcomes among minority patients are multifaceted and complex, involving factors at the patient, provider, and system levels. Although advancements in our understanding of disease biology have led to novel therapeutics for men with advanced prostate cancer, including the introduction of biomarker-driven therapeutics, pivotal translational studies and clinical trials are underrepresented by minority populations. Despite attempts to bridge the disparities gap, there remains an unmet need to expand minority engagement and participation in clinical trials to better define the impact of therapy on efficacy outcomes, quality of life, and role of biomarkers in diverse patient populations. The IRONMAN registry (ClinicalTrials.gov identifier: NCT03151629 ), a global, prospective, population-based study, was borne from this unmet medical need to address persistent gaps in our knowledge of advanced prostate cancer. Through integrated collection of clinical outcomes, patient-reported outcomes, epidemiologic data, and biospecimens, IRONMAN has the goal of expanding our understanding of how and why prostate cancer outcomes differ by race and ethnicity. To this end, the Diversity Working Group of the IRONMAN registry has developed informed strategies for site selection, recruitment, engagement and retention, and trial design and eligibility criteria to ensure broad inclusion and needs awareness of minority participants. In concert with systematic strategies to tackle the complex levels of disparate care, our ultimate goal is to expand minority engagement in clinical research and bridge the disparities gap in prostate cancer care.

8 April 2014 in Neurology
Verified
Journal Article
Closed access
AFAdam Friedant
Adam Friedant
DMDominique Monlezun
Dominique Monlezun
PBPrerana Baranwal
Prerana Baranwal
MVMelisa Valmoria
Melisa Valmoria
ASAmir Shaban
Amir Shaban
SMSheryl Martin-Schild
Sheryl Martin-Schild

6 April 2015 in Neurology
Verified
Journal Article
Closed access
TKTara Kimbrough
Tara Kimbrough
DMDominique Monlezun
Dominique Monlezun
NUNicole Ulrich
Nicole Ulrich
NMNelson Mandrell
Nelson Mandrell
JLJoel Lanceta
Joel Lanceta
SMSheryl Martin-Schild
Sheryl Martin-Schild

8 April 2014 in Neurology
Verified
Journal Article
Closed access
AFAdam Friedant
Adam Friedant
DMDominique Monlezun
Dominique Monlezun
AGAlexander George
Alexander George
RKRamy El Khoury
Ramy El Khoury
SMSheryl Martin-Schild
Sheryl Martin-Schild